Repeated SBRT for in- and out-of-field recurrences in the liver.

Wiederholte SBRT bei In- und Out-of-field Rezidiven der Leber.

Journal

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 25 04 2018
accepted: 09 10 2018
pubmed: 26 10 2018
medline: 21 11 2019
entrez: 25 10 2018
Statut: ppublish

Résumé

To evaluate the feasibility and toxicity profile of repeated stereotactic body radiotherapy (SBRT) for recurrent primary or secondary liver tumors. Consecutive patients with primary (hepatocellular carcinoma [HCC] or cholangiocarcinoma [CCC]) or secondary liver cancer (LM), with intrahepatic recurrence or progression after SBRT, underwent re-SBRT in 3 to 12 fractions with a median time of 15 (range 2-66) months between treatments. In all, 24 patients which were previously treated with SBRT (30 lesions) were retreated with SBRT for "in- and out-of-field" recurrences (2nd SBRT: n = 28, 3rd SBRT: n = 2). The median follow-up after re-irradiation was 14 months. The median prescribed dose for the first SBRT was 46.5 (range 33-66 Gy, EQD2 Repeated liver SBRT is feasible, without excessive liver toxicity, when there is no considerable overlapping with pre-irradiated portions of the stomach or bowel and enough time for the liver to regenerate.

Identifiants

pubmed: 30353350
doi: 10.1007/s00066-018-1385-0
pii: 10.1007/s00066-018-1385-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

246-253

Références

J Clin Oncol. 2001 Jan 1;19(1):164-70
pubmed: 11134209
Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):810-21
pubmed: 12095546
Acta Oncol. 2006;45(7):856-64
pubmed: 16982550
Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1447-52
pubmed: 17996394
Semin Radiat Oncol. 2008 Oct;18(4):215-22
pubmed: 18725106
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S94-100
pubmed: 20171524
Radiat Oncol. 2012 May 18;7:74
pubmed: 22607687
J Clin Oncol. 2013 May 1;31(13):1631-9
pubmed: 23547075
Radiother Oncol. 2014 Jun;111(3):412-7
pubmed: 24906626
J Gastroenterol Hepatol. 2014 Nov;29(11):1919-25
pubmed: 25041220
Strahlenther Onkol. 2014 Oct;190(10):872-81
pubmed: 25091267
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Radiother Oncol. 2014 Nov;113(2):151-7
pubmed: 25613395
J Cancer Res Clin Oncol. 2015 Jul;141(7):1301-9
pubmed: 25644863
Radiat Oncol. 2015 Mar 20;10:69
pubmed: 25889512
Int J Radiat Oncol Biol Phys. 2015 Sep 1;93(1):16-25
pubmed: 26279020
J Cancer. 2015 Aug 01;6(11):1099-104
pubmed: 26516357
J Clin Oncol. 2016 Feb 10;34(5):452-9
pubmed: 26628466
Yonsei Med J. 2016 Jan;57(1):41-9
pubmed: 26632381
Radiat Oncol J. 2015 Dec;33(4):276-83
pubmed: 26756027
J Cancer. 2016 Jan 10;7(3):283-8
pubmed: 26918041
Radiat Oncol. 2016 Jul 02;11(1):89
pubmed: 27369241
Best Pract Res Clin Gastroenterol. 2016 Aug;30(4):603-16
pubmed: 27644908
J Hepatol. 2017 Feb;66(2):338-346
pubmed: 27677714
Am J Clin Oncol. 2018 Jul;41(7):632-637
pubmed: 27755060
Strahlenther Onkol. 2016 Dec;192(12):886-894
pubmed: 27757502
Strahlenther Onkol. 2017 Jun;193(6):433-443
pubmed: 28138949
Radiother Oncol. 2017 May;123(2):227-233
pubmed: 28274491
Rep Pract Oncol Radiother. 2017 Mar-Apr;22(2):96-102
pubmed: 28490979
Semin Radiat Oncol. 2017 Jul;27(3):197-208
pubmed: 28577827
Radiat Oncol. 2017 Jul 12;12(1):116
pubmed: 28701219
Clin Oncol (R Coll Radiol). 2018 Jan;30(1):5-14
pubmed: 29033164
BMC Cancer. 2017 Nov 21;17(1):781
pubmed: 29162055
Strahlenther Onkol. 2018 May;194(5):403-413
pubmed: 29322205
Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):335-343
pubmed: 29353652
Radiat Oncol. 2018 Feb 13;13(1):26
pubmed: 29439707
Int J Radiat Oncol Biol Phys. 2018 Jan 6;:
pubmed: 29482870
BMC Cancer. 2018 Mar 13;18(1):283
pubmed: 29534687
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
Am J Pathol. 1966 Apr;48(4):597-611
pubmed: 5327788
Int J Radiat Oncol Biol Phys. 1995 Feb 15;31(4):883-91
pubmed: 7860402

Auteurs

Eleni Gkika (E)

Departmentof Radiation Oncology, University Medical Center Freiburg, Robert-Koch-Str. 3, 79106, Freiburg im Breisgau, Germany. eleni.gkika@uniklinik-freiburg.de.
University Medical Center Freiburg, Freiburg, Germany. eleni.gkika@uniklinik-freiburg.de.

Iosif Strouthos (I)

Departmentof Radiation Oncology, University Medical Center Freiburg, Robert-Koch-Str. 3, 79106, Freiburg im Breisgau, Germany.

Simon Kirste (S)

Departmentof Radiation Oncology, University Medical Center Freiburg, Robert-Koch-Str. 3, 79106, Freiburg im Breisgau, Germany.

Sonja Adebahr (S)

Departmentof Radiation Oncology, University Medical Center Freiburg, Robert-Koch-Str. 3, 79106, Freiburg im Breisgau, Germany.

Michael Schultheiss (M)

Department of Gastroenterology, Hepatology, Endocrinology and Infectious Diseases, University Medical Center Freiburg, Freiburg, Germany.

Dominik Bettinger (D)

Department of Gastroenterology, Hepatology, Endocrinology and Infectious Diseases, University Medical Center Freiburg, Freiburg, Germany.
Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Ralph Fritsch (R)

Department of Internal Medicine, Hematology, Oncology and Stem-Cell Transplantation, University Medical Center Freiburg, Freiburg, Germany.

Volker Brass (V)

Department of Gastroenterology, Hepatology, Endocrinology and Infectious Diseases, University Medical Center Freiburg, Freiburg, Germany.

Lars Maruschke (L)

Department of Radiology, University Medical Center Freiburg, Freiburg, Germany.

Hannes Philipp Neeff (HP)

Department of General and Visceral Surgery, University Medical Center Freiburg, Freiburg, Germany.

Sven Arke Lang (SA)

Department of General and Visceral Surgery, University Medical Center Freiburg, Freiburg, Germany.

Ursula Nestle (U)

Departmentof Radiation Oncology, University Medical Center Freiburg, Robert-Koch-Str. 3, 79106, Freiburg im Breisgau, Germany.
Partner Site Freiburg, German Cancer Consortium (DKTK), Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Department of Radiation Oncology, Kliniken Maria Hilf, Mönchengladbach, Germany.

Anca-Ligia Grosu (AL)

Departmentof Radiation Oncology, University Medical Center Freiburg, Robert-Koch-Str. 3, 79106, Freiburg im Breisgau, Germany.
Partner Site Freiburg, German Cancer Consortium (DKTK), Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.
German cancer Research Center (DKFZ), Heidelberg, Germany.

Thomas Baptist Brunner (TB)

Departmentof Radiation Oncology, University Medical Center Freiburg, Robert-Koch-Str. 3, 79106, Freiburg im Breisgau, Germany.
Partner Site Freiburg, German Cancer Consortium (DKTK), Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.
German cancer Research Center (DKFZ), Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH